Skip to main content
CGC
NASDAQ Life Sciences

Canopy Growth Discloses Non-Reliance on Past Financials, Expects Restatement and Material Weakness

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$1.03
Mkt Cap
$470.181M
52W Low
$0.844
52W High
$2.38
52W Position info
22% above low
Off High info
57% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

CGC sits 22% above its 52-week low of $0.844.

Summary

Canopy Growth announced it cannot rely on its past two years of financial statements due to accounting errors, will restate them, and expects to report a material weakness in internal controls.


Key Events · Legal and Risk Events · CGC

  • Non-Reliance on Financial Statements

    The company's audited consolidated financial statements for fiscal years ended March 31, 2024, and March 31, 2025, and several unaudited interim periods, should no longer be relied upon.

  • Reason for Restatement

    The non-reliance is due to non-cash technical errors in accounting related to the classification of certain share-settled warrants as equity instead of liabilities.

  • Material Weakness in Internal Controls

    Management expects to report a material weakness in the company's internal control over financial reporting.

  • Restatement Plan

    The company intends to restate the affected financial statements in its Annual Report on Form 10-K for the fiscal year ended March 31, 2026, expected to be filed on June 15, 2026.


Analysis · CGC · Life Sciences

Canopy Growth announced that its financial statements for fiscal years 2024 and 2025, along with several interim periods, can no longer be relied upon due to technical accounting errors related to the classification of share-settled warrants. The company expects to report a material weakness in internal controls and will restate these financials in its upcoming 10-K. While the company states these are non-cash adjustments not impacting revenue, cash flows, liquidity, or debt covenants, the inability to rely on past financial reports and the disclosure of a material weakness are significant concerns for investors regarding financial transparency and control. The voluntary application for a management cease trade order further underscores the seriousness of the situation.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CGC was trading at $1.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $470.2M. The 52-week trading range was $0.84 to $2.38. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CGC - Latest Insights

CGC
Nov 06, 2026, 12:47 PM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $0.6144
Real-time Price: $0.4329 info
Change: -$0.1815 (-30%) info
Market Cap: $194.121M info
CGC
Nov 06, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.690
Real-time Price: $0.4329 info
Change: -$0.2571 (-37%) info
Market Cap: $194.121M info
CGC
Nov 06, 2026, 6:45 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.700
Real-time Price: $0.4329 info
Change: -$0.2671 (-38%) info
Market Cap: $194.121M info
CGC
Oct 23, 2026, 5:19 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.673
Real-time Price: $0.4329 info
Change: -$0.2401 (-36%) info
Market Cap: $194.121M info
CGC
Oct 16, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7183
Real-time Price: $0.4329 info
Change: -$0.2854 (-40%) info
Market Cap: $194.121M info